mProX™ Human HRH2 Stable Cell Line

Ye S, et al. "Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal ." International journal of biological sciences, 2023.
Clear cell renal cell carcinoma (ccRCC) is an aggressive urological cancer that arises from the proximal tubular epithelium. The role of protein arginine methylation, a common post-translational modification, in various cancer-related biological functions, particularly in cancer immunity, has been well-established. To provide better individualized clinical management for ccRCC patients, a protein arginine methylation-related prognostic signature called PRMTScore was developed using a machine-learning algorithm. The reliability of the PRMTScore was validated in two external clinical cohorts receiving immunotherapy. An integrated approach of multi-omics analysis, multiplex immunohistochemistry, and proteomic profiling revealed distinct subtypes of ccRCC based on their PRMTScore, which correlated with prognosis, genomic alterations, tumor microenvironment characteristics, immune checkpoint expressions, and response to immunotherapy. Notably, the study also identified the tumor-suppressive role of PRMT5 in ccRCC, with low expression of PRMT5 predicting worse outcomes and higher levels of PD1(+) CD8(+) cells. Overall, the findings suggest that the PRMTScore system has potential clinical utility in predicting prognosis, immune response and guiding treatment decisions for ccRCC patients. This is the first study to highlight the tumor suppressive role of PRMT5 in ccRCC.
Pubmed: 37781030   DOI: 10.7150/ijbs.80323

Xiang J, et al. "Deciphering the implications of mitophagy-related signatures in clinical outcomes ." Journal of cancer research and clinical oncology, 2023.
The study highlights the role of mitophagy in various cancer-related biological processes, specifically in clear cell renal cell carcinoma (ccRCC). A comprehensive analysis of 25 mitophagy-related genes in 763 ccRCC samples revealed distinct patterns, which were further used to construct a predictive signature (RiskScore) to assess the mitophagy status of individual patients. The study also investigated the effect of PTEN-induced putative kinase 1 (PINK1) on ccRCC prognosis and immune microenvironment using immunofluorescence and immunohistochemistry staining. Results showed significant differences in gene expression, genomic variations, and patient outcomes among three clusters identified through consensus clustering. The study further identified eight key genes for constructing the predictive signature, with strong prognostic value for ccRCC patients. The RiskScore was found to be associated with immune checkpoint expression, immune cell abundance, and response to immunotherapy. A nomogram based on clinical features and the RiskScore was constructed with robust predictive power. Notably, PINK1 expression was found to be linked with positive treatment response and advanced stages of tertiary lymphoid structures, indicating its potential for boosting anti-tumor immunity in ccRCC patients. These findings provide valuable insights into the role of mitophagy in ccRCC and emphasize the importance of PINK1 in mediating treatment response and immune microenvironment in these patients.
Pubmed: 37689589   DOI: 10.1007/s00432-023-05349-y